Rare diseases
Investigational molecules
Locations
Building E, Epfl Innovation Park, 1015
AB2 Bio S.A. concentrates its research efforts on developing innovative treatments for cancer, with particular emphasis on hematological malignancies. The company's therapeutic pipeline targets specific forms of blood cancers, reflecting a strategic focus on addressing unmet medical needs within oncology.
The sponsor's research activities demonstrate a commitment to advancing treatment options for patients with hematologic disorders, positioning the organization within the specialized field of hemato-oncology drug development.
AB2 Bio S.A. runs clinical trials in conditions such as Familial haemophagocytic lymphohistiocytosis, X-linked lymphoproliferative syndrome, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
GermanyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
